STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology
drugs-4

Hims & Hers Shares Plunge as FDA Tightens Grip on Compounded GLP-1 Drugs

byLuca Blaumann
February 9, 2026
in Biotechnology, Large-Cap
Reading Time: 2 mins read
Share on TwitterShare on LinkedIn

Regulatory crackdown and Novo Nordisk lawsuit rattle investors and reshape weight-loss drug landscape

Shares of Hims & Hers Health (HIMS) tumbled as much as 27% early Monday after the Food and Drug Administration signaled it would take “decisive steps” to crack down on the sale and marketing of compounded GLP-1 weight-loss drugs. The selloff deepened investor concerns about the sustainability of a key growth driver for the telehealth company, which has offered lower-cost, compounded alternatives to popular branded medications.

In a statement released Friday, the FDA said it intends to restrict the use of GLP-1 active pharmaceutical ingredients in non-FDA-approved compounded drugs that are being mass-marketed as substitutes for approved therapies. The agency specifically called out companies that promote compounded products in ways that blur the line with branded drugs, emphasizing that such medications cannot be marketed as generics, claimed to be the same as FDA-approved drugs, or advertised as clinically proven.

The regulatory pressure intensified further on Monday when Novo Nordisk, the maker of Ozempic, filed a lawsuit seeking to block Hims & Hers from selling compounded versions of its GLP-1 medications. The legal action underscores growing pushback from branded drugmakers, who argue that compounded alternatives undermine intellectual property protections and patient safety standards.

Hims & Hers has built significant demand by offering compounded GLP-1 treatments at prices well below branded options like Ozempic from Novo Nordisk and Mounjaro from Eli Lilly. While these compounded drugs contain the same active ingredient, they are not FDA-approved and are subject to stricter limitations on advertising and distribution.

The market reaction was swift and severe. With Monday’s decline, Hims & Hers shares are down roughly 50% year to date, a dramatic reversal from their February 2025 peak near $68. Investors now face a pivotal question: whether the company can pivot growth away from compounded GLP-1s and toward its broader telehealth platform, or if heightened regulatory scrutiny will materially constrain its business model going forward.

You might like this article:Stellantis Takes $26 Billion EV Write-Down as Electrification Strategy Resets

Tags: GrowthHIMSMoversNewsStock Market
Previous Post

Stellantis Takes $26 Billion EV Write-Down as Electrification Strategy Resets

Next Post

Oracle Rebounds as Big Tech’s AI Spending Revives Software Optimism

Related Posts

Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders

byLiliana Vida
November 20, 2026
0

GraniteShares’ 2x long AIL and 2x short ANS ETFs give traders daily leveraged exposure to Anthropic stock. Launch date, how...

chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

byLiliana Vida
November 17, 2026
0

Pivotal REGAL trial demonstrates significant survival benefits, positioning the company for a potential FDA submission in 2027. SELLAS Life Sciences...

semiconductor-6

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

byLuca Blaumann
November 12, 2026
0

Cristiano Amon highlights strong semiconductor demand, supply shortages, and Qualcomm’s growing AI infrastructure ambitions despite widespread technology stock volatility. Qualcomm...

Next Post
investing

Oracle Rebounds as Big Tech’s AI Spending Revives Software Optimism

Latest News

Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

Based on Your Interest

Artificial Intelligence

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

November 11, 2026
Artificial Intelligence

CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

November 10, 2026
investing
Artificial Intelligence

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

November 10, 2026

Recommended

Auto Manufacturers

Lucid Secures $1.75 Billion Liquidity Boost From Saudi PIF to Support Turnaround

November 10, 2026
Artificial Intelligence

KULR Technology Revenue Surges 197% in Q3 as Battery Sales Nearly Quadruple

November 10, 2026
Aerospace & Defense

Rocket Lab Q3 Revenue Surges 73% to $268 Million, Beating Wall Street Expectations

November 9, 2026
Artificial Intelligence

IonQ Shares Climb as Company Expands Government Reach Through Carahsoft Partnership

November 9, 2026
Aerospace & Defense

AST SpaceMobile and Rakuten Launch Joint Venture Backed by $1 Billion in Japanese Government Funding

November 9, 2026
Stoxpo

Follow us on social media:

Highlights

  • Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders
  • KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems
  • SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results
  • Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers
  • D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders

November 20, 2026

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

November 18, 2026
chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

November 17, 2026
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.